Lysenze-D Tablet is a combination pharmaceutical formulation containing Diclofenac 50 mg and Serratiopeptidase 10 mg, designed for the management of pain and inflammation associated with various musculoskeletal and inflammatory conditions. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effect by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Serratiopeptidase, a proteolytic enzyme, complements this action by facilitating the breakdown of inflammatory mediators and promoting the resolution of edema and swelling. This synergistic combination is particularly effective in conditions such as arthritis, postoperative inflammation, soft tissue injuries, and other acute or chronic inflammatory disorders. Lysenze-D is indicated for short-term use to alleviate pain, reduce inflammation, and improve functional mobility. It should be used under medical supervision, especially in patients with a history of gastrointestinal ulcers, bleeding disorders, or hypersensitivity to NSAIDs. Common side effects may include gastrointestinal discomfort, nausea, or allergic reactions. Caution is advised in patients with renal or hepatic impairment. Overall, Lysenze-D Tablet offers a balanced approach to managing inflammatory pain by combining analgesic and proteolytic mechanisms, enhancing patient comfort and recovery.